Lv7
3360 积分 2023-05-06 加入
Cost‐effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma
1个月前
已完结
Factors reducing omalizumab response in severe asthma
8个月前
已完结
The standardized and mini versions of the PAQLQ are valid, reliable, and responsive measurement tools
8个月前
已完结
Tuberous sclerosis
1年前
已完结
Bidirectional interaction of airway epithelial remodeling and inflammation in asthma
1年前
已完结
Might biologics serve to interrupt the atopic march?
1年前
已完结
Total immunoglobulin E in infant bronchiolitis and risk of developing asthma
1年前
已完结
[Clinical efficacy observation of omalizumab on patients with moderate to severe allergic asthma for one year]
1年前
已完结
Omalizumab in CSU: Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation
1年前
已完结
An Update on Monoclonal Antibody Therapy to Treat Moderate-to-Severe Asthma: Benefits, Choices, and Limitations
1年前
已完结
皖公网安备34019202002308
